Pharsight

Pradaxa is owned by Boehringer Ingelheim.

Pradaxa contains Dabigatran Etexilate Mesylate.

Pradaxa has a total of 9 drug patents out of which 1 drug patent has expired.

Expired drug patents of Pradaxa are:

US6087380*PED

Pradaxa was authorised for market use on 19 October, 2010.

Pradaxa is available in capsule;oral dosage forms.

Pradaxa can be used as method of reversing the anticoagulant effect of dabigatran using idarucizumab.

The generics of Pradaxa are possible to be released after 20 July, 2031.

Application	Filing Date	Opposition Party	Legal Status
EP03743368A	2013-04-03	Sanovel IIaç San. ve Tic. A.S.	Patent maintained as amended
EP03743368A	2013-03-27	Stötter, Gerd	Patent maintained as amended
EP07115663A	2012-10-10	Sanovel IIaç San. ve Tic. A.S.	Revoked
EP07115663A	2012-10-05	Stötter, Gerd	Revoked
EP09153155A	2012-07-13	PONS PATENTES Y MARCAS INTERNACIONAL, S.L.	Revoked
EP09153155A	2012-07-12	Sanovel Ilac Sanayii ve Ticaret A.S.	Revoked
EP09153155A	2012-07-06	Stötter, Gerd	Revoked
EP04764411A	2010-01-29	APOTEX INC.	Opposition rejected

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7932273	BOEHRINGER INGELHEIM	3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament	Sep, 2025 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6087380 (Pediatric)	BOEHRINGER INGELHEIM	Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions	Jun, 2022 (11 months ago)
US9925174	BOEHRINGER INGELHEIM	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof	Jun, 2023 (12 days from now)
US9925174 (Pediatric)	BOEHRINGER INGELHEIM	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof	Dec, 2023 (6 months from now)
US7932273 (Pediatric)	BOEHRINGER INGELHEIM	3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament	Mar, 2026 (2 years from now)
US7866474	BOEHRINGER INGELHEIM	Film container	Aug, 2027 (4 years from now)
US7866474 (Pediatric)	BOEHRINGER INGELHEIM	Film container	Mar, 2028 (4 years from now)
US9034822	BOEHRINGER INGELHEIM	Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds	Jan, 2031 (7 years from now)
US9034822 (Pediatric)	BOEHRINGER INGELHEIM	Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds	Jul, 2031 (8 years from now)